4-bromo-3-methoxy-N,N-dimethylaniline | 90642-46-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-bromo-3-methoxy-N,N-dimethylaniline
• CAS: 90642-46-9
• 化学式: C₉H₁₂BrNO
• 分子量: 230.104
• InChiKey: FJFASOHNLDGZGR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-bromo-3-methoxy-N,N-dimethylaniline 在 正丁基锂 、 二氧化硫 、 N-氯代丁二酰亚胺 作用下， 以 四氢呋喃 为溶剂， 以5.11 %的产率得到4-(dimethylamino)-2-methoxybenzenesulfonyl chloride
  参考文献：
  名称：

  WO2023/16484

  摘要：

  公开号：
• 作为产物：
  描述：

  3-甲氧基-N,N-二甲基苯胺-N-氧化物 在 二溴亚砜 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 4.75h， 以39%的产率得到4-bromo-3-methoxy-N,N-dimethylaniline
  参考文献：
  名称：

  亚硫酰卤处理N，N-二烷基苯胺N-氧化物合成卤代苯胺

  摘要：

  N，N-二烷基苯胺N-氧化物的特殊反应性使得可以方便实用地获得富含电子的芳基卤化物。一对互补的反应协议允许用于选择性对-bromination或邻位的-chlorination N，N- -dialkylanilines在高达69％的分离收率。通过将N，N-二烷基苯胺暂时氧化为相应的N，N-二烷基苯胺N-氧化物并去除生成的弱N – O ，可以生成各种卤化苯胺 通过在低温下用亚硫酰溴或亚硫酰氯处理可实现键合。

  DOI：

  10.1021/acs.joc.8b01590

文献信息

• Highly Linear Selective Cobalt-Catalyzed Addition of Aryl Imines to Styrenes: Reversing Intrinsic Regioselectivity by Ligand Elaboration
  作者：Wengang Xu、Naohiko Yoshikai

  DOI：10.1002/anie.201408028

  日期：2014.12.15

  Highly linear selective, imine‐directed hydroarylation of styrene has been achieved with cobalt‐based catalytic systems featuring bis(2,4‐dimethoxyphenyl)(phenyl)phosphine and either 2‐methoxypyridine or DBU as a ligand and a Lewis base additive, respectively, thus affording a variety of 1,2‐diarylethanes (bibenzyls) in good yields under mild reaction conditions. The triarylphosphine controls the regioselectivity

  使用基于双（2,4-二甲氧基苯基）（苯基）膦和2-甲氧基吡啶或DBU分别作为配体和Lewis碱添加剂的钴基催化体系，可以实现苯乙烯的高度线性选择性，亚胺定向的氢芳基化反应，因此，在温和的反应条件下，可以提供高收率的各种1,2-二芳基乙烷（联苄）。三芳基膦控制区域选择性，而路易斯碱则显着加速反应。配体筛选和氘标记研究提供了有关配体和路易斯碱在关键的CC还原消除步骤中的作用的暗示。
• 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle
  申请人：Sekiguchi Yoshinori

  公开号：US20080318923A1

  公开（公告）日：2008-12-25

  It is intended to provide a drug which is efficacious against pathological conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, it is intended to provide a drug which has a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. As the results of intensive studies, a novel 1,3-dihydro-2H-indol-2-one compound and a pyrrolidin-2-one compound fused with a heteroaromatic ring, which are highly selective antagonists of arginine-vasopressin V1b receptor, have high metabolic stabilities and show favorable brain penetration and high plasma concentrations, are found, thereby achieving the above objective.

  本发明旨在提供一种对精氨酸加压素V1b受体相关的病理状况具有疗效的药物。更具体地说，本发明旨在提供一种具有治疗或预防抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、消化系统疾病、药物成瘾、癫痫、脑梗塞、脑缺血、脑水肿、头部损伤、炎症、免疫系统疾病、脱发等作用的药物。经过深入研究，发现了一种新型的1,3-二氢吲哚-2-酮化合物和一种与杂环芳香族环融合的吡咯烷-2-酮化合物，它们是精氨酸加压素V1b受体高度选择性的拮抗剂，具有高代谢稳定性、良好的脑穿透力和高血浆浓度，从而实现了上述目标。
• 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle
  申请人：Taisho Pharmaceutical Co., Ltd.

  公开号：US08030499B2

  公开（公告）日：2011-10-04

  It is intended to provide a drug which is efficacious against pathological conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, it is intended to provide a drug which has a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. As the results of intensive studies, a novel 1,3-dihydro-2H-indol-2-one compound and a pyrrolidin-2-one compound fused with a heteroaromatic ring, which are highly selective antagonists of arginine-vasopressin V1b receptor, have high metabolic stabilities and show favorable brain penetration and high plasma concentrations, are found, thereby achieving the above objective.

  本发明旨在提供一种对精氨酸加压素V1b受体相关的病理状况有效的药物。更具体地说，本发明旨在提供一种对抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、饮食失调、高血压、消化系统疾病、药物成瘾、癫痫、脑梗死、脑缺血、脑水肿、头部损伤、炎症、免疫性疾病、脱发等具有治疗或预防作用的药物。经过密集研究，发现了一种新型的1,3-二氢吲哚-2-酮化合物和一种与杂环芳香环融合的吡咯烷-2-酮化合物，它们是高度选择性的精氨酸加压素V1b受体拮抗剂，具有高代谢稳定性、良好的脑穿透性和高血浆浓度，从而实现了上述目标。
• Fluorescent phosphoinositide 3-kinase inhibitors suitable for monitoring of intracellular distribution
  作者：Donghee Kim、Hyunseung Lee、Hwiseok Jun、Soon-Sun Hong、Sungwoo Hong

  DOI：10.1016/j.bmc.2011.03.025

  日期：2011.4

  The monitoring of the drug behavior and distribution in biological system can provide information whether drug reaches its desired target, and a biological rationale for the design of new therapeutics. We have developed a family of potent fluorescent PI3K alpha inhibitors in which part of the fluorophore was engineered to be a pharmacophore capable of inhibiting PI3K alpha. These xanthine derivatives are characterized by a donor-acceptor molecular structure, and changes in the electronic properties of the two variation points at R-1 and R-2 give rise to notable bathochromic shifts in the lambda(em), (abs) and increase the value of Phi(F). Further, we illustrated the use of E2 (PI3K alpha/IC50 = 0.068 mu M, T47D cell viability: IC50 = 0.9 mu M) to block cancer cell proliferation and to monitor its subcellular localization by fluorescence microscopy. (C) 2011 Elsevier Ltd. All rights reserved.